Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 14/20 | 0.49 |
| ▸ | TLR7 | Q9NYK1 | 12/20 | 0.49 |
| ▸ | DCK | P27707 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5090069 | 0.96 | TLR8 (0.51) | TLR8TLR7DCKALDH1A1 | |
| SCHEMBL5090073 | 0.94 | TLR8 (0.52) | TLR8TLR7DCKALDH1A1 | |
| SCHEMBL5089142 | 0.90 | TLR8 (0.48) | TLR8TLR7DCKALDH1A1 | |
| SCHEMBL5095712 | 0.86 | TLR8 (0.52) | TLR8TLR7 | |
| SCHEMBL5096289 | 0.85 | TLR8 (0.57) | TLR8TLR7 | |
| SCHEMBL5095707 | 0.83 | TLR8 (0.59) | TLR8TLR7 | |
| SCHEMBL5095445 | 0.82 | CA12 (0.46) | TLR8TLR7 | |
| SCHEMBL5087214 | 0.82 | TLR8 (0.58) | TLR8TLR7 | |
| SCHEMBL5090124 | 0.82 | TLR8 (0.53) | TLR8TLR7 | |
| SCHEMBL5089041 | 0.82 | TLR8 (0.60) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120128715-A1 | METHOD FOR STIMULATING THE IMMUNE RESPONSE OF NEWBORNS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-05-24 | — | — | US | claimed |
| US-20080193468-A1 | Method for Stimulating the Immune Response of Newborns | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2008-08-14 | — | — | US | claimed |
| WO-2006029223-A2 | METHOD FOR STIMULATING THE IMMUNE RESPONSE OF NEWBORNS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2006-03-16 | — | — | WO | claimed |
| US-20180057509-A1 | ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES CO (US) | 2018-03-01 | — | — | US | disclosed |
| US-20180057509-A1 | ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES CO (US) | 2018-03-01 | — | — | US | disclosed |
| US-20170088559-A1 | ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES CO (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170088559-A1 | ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES CO (US) | 2017-03-30 | — | — | US | disclosed |
| US-9546184-B2 | Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2017-01-17 | — | — | US | disclosed |
| US-9546184-B2 | Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2017-01-17 | — | — | US | disclosed |
| US-20150266901-A1 | ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES CO (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266901-A1 | ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES CO (US) | 2015-09-24 | — | — | US | disclosed |
| EP-1846419-B1 | Alkoxy-substituted thiazoloquinolines and thiazolonaphthyridines | 3M INNOVATIVE PROPERTIES CO (US) | 2014-04-16 | — | — | EP | disclosed |
| US-20120128715-A1 | METHOD FOR STIMULATING THE IMMUNE RESPONSE OF NEWBORNS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-05-24 | — | — | US | disclosed |
| US-20080318998-A1 | Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080318998-A1 | Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080318998-A1 | Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080193468-A1 | Method for Stimulating the Immune Response of Newborns | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2008-08-14 | — | — | US | disclosed |
| EP-1846419-A2 | ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006086449-A2 | ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006029223-A2 | METHOD FOR STIMULATING THE IMMUNE RESPONSE OF NEWBORNS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266901-A1 | ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | IL2, IFNG, TSLP | TLR8 97/4885TLR7 36/4885DCK 286/4885 |
| US-20170088559-A1 | ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | IL2, IFNG, TSLP | TLR8 97/4885TLR7 36/4885DCK 286/4885 |
| US-20080318998-A1 | Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines | IL2, IFNG, TSLP | TLR8 97/4885TLR7 36/4885DCK 286/4885 |
| US-20180057509-A1 | ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | IL2, IFNG, TSLP | TLR8 97/4885TLR7 36/4885DCK 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.